Targeting voltage-gated sodium channels for pain therapy

Area of Science:

• Pharmacology
• Neuroscience
• Drug Discovery

Background:

• Voltage-gated sodium channels (Nav) are established targets for pain management, with local anesthetics and anticonvulsants demonstrating analgesic properties.
• Traditional drug discovery methods yielded Nav inhibitors with limited therapeutic windows, hindering clinical utility.
• Recent identification of Nav1.7 channel mutations conferring pain insensitivity has revitalized research.

Purpose of the Study:

• To review recent advancements in the development of novel Nav channel inhibitors for pain therapy.
• To summarize current findings on emerging Nav inhibitors, focusing on Nav1.7.
• To highlight remaining challenges and unanswered questions in the clinical development of these agents.

Main Methods:

• Review of scientific literature on voltage-gated sodium channel inhibitors and pain therapy.
• Analysis of recent discoveries in ion channel genetics, particularly Nav1.7 mutations.
• Synthesis of current research on emerging Nav inhibitors and their therapeutic potential.

Main Results:

• Significant progress has been made in developing Nav inhibitors, driven by genetic insights into Nav1.7.
• New technologies facilitate the targeting of ion channels for drug development.
• Several novel Nav inhibitors are showing promise, though clinical development is ongoing.

Conclusions:

• Emerging Nav inhibitors, particularly targeting Nav1.7, represent a promising new class of analgesics.
• Further research and technological advancements are crucial to overcome challenges in clinical translation.
• The development of effective and safe Nav channel blockers for pain management is an active and evolving field.